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Background. The International Classiﬁcation of Disease, ninth revision (ICD-9) is designed to code disease into categories which
are placed into administrative databases. These databases have been used for epidemiological studies. However, the categories used
in the ICD9-codes are not always the most eﬀective for evaluating speciﬁc diseases or their outcomes, such as the outcomes of
cancer treatment. Therefore a re-classiﬁcation of the ICD-9 codes into new categories speciﬁc to cancer outcomes is needed.
Methods. An expert panel comprised of two physicians created broad categories that would be most useful to researchers
investigating outcomes and morbidities associated with the treatment of cancer. A Senior Data Coordinator with expertise in
ICD-9 coding, then joined this panel and each code was re-classiﬁed into the new categories. Results. Consensus was achieved
for the categories to go from the 17 categories in ICD-9 to 39 categories. The ICD-9 Codes were placed into new categories,
and subcategories were also created for more speciﬁc outcomes. The results of this re-classiﬁcation is available in tabular form.
Conclusions. ICD-9 codes were re-classiﬁed by group consensus into categories that are designed for oncology survivorship
research. The novel re-classiﬁcation system can be used by those involved in cancer survivorship research.
1.Background
The importance of a classiﬁcation system for the grouping of
causes of morbidity or mortality has long been known to be
crucial for the study of disease. The ﬁrst attempt to classify
disease systematically has been attributed to Francois Bossier
de Lacroix, (1706–1777), better known as Sauvages [1]i n
his treatise Nosologia Methodica, written in the 18th century.
Subsequently, many groups have made attempts to create
their own classiﬁcation systems to compile quantitative data
about various diseases within diﬀerent population groups.
In these systems, individual code categories are assigned to
conditions that occur frequently and are associated with
signiﬁcant morbidity; others are grouped together, often by
anatomical site or physiologic system [2]. Since the early
1900’s, international collaborations have attempted to revise
and update these classiﬁcation systems and this has led
to the development of the International Classiﬁcation of
Diseases, which is now under the direction of the World
Health Organization. The ﬁrst version of the International
Classiﬁcation of Diseases was adopted in 1900. The ninth
version, known as ICD-9, was published in 1975 and uses a
ﬁve-digit coding system where the categories are meaningful
at the 3-digit level [3].
The ICD-9 has become a useful tool for health
researchers, as the use of administrative databases in the
study of diseases has ﬂourished over the last decade. Admin-
istrative databases provide a quick and eﬃcient method of
eliciting clinical information regarding hospitalization, as
compared to the historically used gold standard of chart
review. These administrative databases were not intended for
research but rather to collect information regarding resource
utilization. However, studies have shown that clinical data
extracted from hospital databases in Canada provide reliable
data when compared to manual chart review [4]. There are
limitations to these databases; it has been suggested that2 Journal of Cancer Epidemiology
comorbidities in these databases may be underreported for
certain codes [5].
A reorganization of ICD-9 codes has been completed
for four major chronic conditions (coronary artery disease,
congestive heart failure, asthma, and chronic obstructive
pulmonarydisease)byagroupofresearchersforthepurpose
of creating a consistent research tool for the study of these
health problems [6]. These researchers used the consensus of
experts in the ﬁeld and followed the recommendations made
byFinketal.[7].Theirrecommendationsstatedthatagroup
consensus should focus on a carefully deﬁned problem that
could be investigated in a timely and economical way, that
consensus panel members should be representative of their
profession, and that decisions on important issues should be
justiﬁed by available empirically derived data as well as by
judgments and experience.
The Childhood/Adolescent/Young Adult Cancer Sur-
vivor Program (CAYACS) is a research program investigating
late outcomes in survivors of pediatric and young adult
cancer through the linkage of administrative databases. One
of the major aims of this program was to analyze hospi-
talizations in survivors of childhood and adolescent cancer
occurring 5 years after the date of diagnosis. ICD-9 codes
reported on the hospital separation forms of 5-year cancer
survivors can be linked and compared with controls who did
not have childhood cancer. In reviewing the ICD-9 coding
book, it became clear that the categories used in this book
were not ideally suited for research into cancer survivorship.
Therefore, a reclassiﬁcation of ICD-9 coding was needed
that was speciﬁc for all cancer survivorship issues. The
purpose of this paper is to develop this reclassiﬁcation of the
ICD-9 codes that can be used by all researchers in cancer
survivorship. Speciﬁcally, this reclassiﬁcation system can be
used by researchers interested in iatrogenic late eﬀects due
to therapies given to patients with cancer. It can also be
used to study the association of cancer with other diseases
that may share etiologic determinants. Finally, it can also
be used in Health Services research investigating the rates
of hospitalizations or medical services use in those who had
previously treated cancer.
2. Methods
The ﬁrst step was to review the categories used in the ICD-
9 and then to decide what categories would be useful for
oncology outcome research. Two investigators (SRR and
KG) decided which major categories should be included.
These categories included both main categories and a few
s u b c a t e g o r i e sa sr e q u i r e d .I tw a sd e c i d e dt ou s eac a t e g o r y
called “other” to group together all codes which were not
easily identiﬁable or did not seem as important for oncology
research.
T h es e c o n ds t e pw a st h e nt oc r e a t ea ne x p e rtp a n e lw h i c h
included a radiation oncologist, a pediatric oncologist, and a
data coordinator with extensive knowledge in ICD-9 coding
(KG, SRR, LL). All 3 members of the panel had experience
in survivorship research and were involved in a study using
administrative databases to look at long-term outcomes in
children treated for cancer (the CAYACS program). This
panel then systematically reviewed each code in the ICD-9
coding book and placed each code into its new category in
an Excel database.
The ﬁnal step was the transformation of this spreadsheet
(performed by ML) into a program that reads ICD-9 codes
from a data ﬁle and assigns the correct category using R code
(reference), so that this new database could be easily used in
future studies.
3. Results
The categories decided upon by the panel are shown in
Table 1. This changed the number of major categories from
the 17 found in ICD-9 to 39 categories. The categories ﬁrst
usedtheICD-9categoriesservedasabackboneandthennew
categories were created to encompass groups of conditions
that would be of interest to those involved in survivorship
research. After long discussion, the 2 clinicians involved in
thestudydeterminedthatthesewerethecategoriesofchoice.
The reclassiﬁcation of the ICD-9 codes into the new
categories is shown in Table 2. All the codes from the ICD-9
book were able to be incorporated into the new classiﬁcation
groups. The group was able to achieve full consensus for
all codes. The majority of codes were easy to place into the
new categories, but there were many codes that did not ﬁt
easily into a speciﬁc category. However, group consensus was
achieved for all the reclassiﬁcation choices.
4. Discussion
The development of the ICD-9 codes has enabled health
administrators and policy makers to investigate the fre-
quency and causes for hospitalizations across jurisdictions.
This coding system categorizes headings into 17 major
groupings. There has been recent interest in the use of
these hospital administrative databases to help answer
epidemiological hypotheses. However, as the coding system
is generalized to the entire spectrum of health conditions,
it is not ideal for speciﬁc groups of interest. This became
evident to our CAYACS program when we were attempting
to use ICD-9 codes to analyze causes of hospitalizations
in cancer survivors. The existing numerical groupings were
not ideal for survivorship research. For instance, causes
of infections were scattered throughout the ICD-9 coding
groupings despite having infection as a major grouping. The
hospital’s data coordinator could code an infection based on
the pathogen (codes 001-139.8) or could code based on the
system aﬀected by the infection (codes scattered throughout
the range). For a clinical researcher who is interested in all
infections in a group of individuals with a speciﬁc health
condition, the ICD-9 code groupings are not suited for this
type of research. This becomes even more important when
considering a very speciﬁc area of research, such as the
treatment of cancer and its late outcomes. The purpose of
this study was to reclassify the ICD-9 codes into practical
groupings that can be used by a health researcher speciﬁcally
for cancer follow-up outcomes.
This study has therefore reclassiﬁed the ICD-9 codes into
categories which are useful to those involved in oncologyJournal of Cancer Epidemiology 3
Table 1: Categories created by the panel.
Infectious disorders Infertility disorders
Neoplasms Perinatal conditions
Endocrine disorders Skin and subcutaneous disorders
Nutritional disorders Musculoskeletal and connective tissue disorders
Fluid and electrolyte disorders Congenital anomalies
Inherited metabolic, and immune disorders Nonspeciﬁc abnormal ﬁndings
Hematologic disorders Other and unspeciﬁed mortality and morbidity
Psychiatric disorders Injuries
Substance abuse Poisonings by drugs, medicaments, and biological
Neurological disorders substances
ENT and eye disorders Eﬀects of foreign body entering through oriﬁce
Cardiovascular disorders Toxic eﬀects of substances
Varicose veins, haemorrhoids, and lymphatic Other and unspeciﬁed eﬀects of external causes
Disorders Certain adverse eﬀects not elsewhere classiﬁed
Respiratory disorders Complications from a Procedure or Device
Dental disorders Complications of Medical Care
Digestive system disorders Late Eﬀects
Genitourinary disorders External Causes (E Codes)
Gynecological disorders Factors Inﬂuencing Health Status and Contact with
Breast disorders Health Services (V Codes)
Pregnancy, childbirth, and puerperium Morphology of Neoplasms (M Codes)
research using administrative databases. This reclassiﬁcation
system can be used by all groups looking at causes of
hospitalizationinthosediagnosedwithcancer,whetherthese
patientsareonactivetreatmentorareinposttherapysurveil-
lance as long-term survivors. All the codes in ICD-9 are
accounted for and have been placed into speciﬁc categories.
Subcategories were created that would help distinguish areas
of interest within larger groups. For instance, within the
cardiovascular system it is important to distinguish hyper-
tension, myocardial infarction, arrhythmias, valvular disease
and cardiomyopathy from each other, as each subcategory
would likely have diﬀering attributable factors and risks. By
separating out these diﬀerent conditions, we can study the
thelong-termriskofhospitalizationassociatedwithdiﬀerent
initial childhood cancer diagnoses and therapies. We can for
example,measuretheriskofhospitalizationfordiﬀerentcar-
diac conditions in long-term survivors treated for childhood
Hodgkin lymphoma treated with mantle radiotherapy.
A strength of this study is that consensus was easily
achieved for all ICD-9 codes between the 3 members of
the panel. The inclusion of a senior data coordinator who
has extensive experience and expertise in coding in hospital
dischargesgaveinsightintothepracticalityofcoding.Asall3
members of the panel are involved in survivorship research,
the new classiﬁcation scheme was based on experience with
data derived from ICD9-coding.
The main limitation of this study is that it represents
the opinion of only one group of clinicians. Certainly others
may have a few subtle changes they would suggest to the
classiﬁcations or the categories in general.
5. Conclusions
By our accounts this is the ﬁrst reclassiﬁcation of the ICD-
9 codes into new diagnostic groupings that are more useful
for the clinical researcher. Moreover, this new classiﬁcation
system is ideal for oncology-speciﬁc outcomes and can
therefore be used by all researchers in the study of cancer
treatment and survivorship.
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Table 2: Full categorization of ICD-9 codes.
Infectious Disorders
001–136, 320–326, 370.1, 370.3–370.5, 372.0-372.1, 373.4–373.6,
377.3, 380.1, 382, 383.0–383.2, 420–422, 447.7, 460-466, 480-487,
511.1, 513, 540.1, 567.0-567.2, 573.1-573.2, 577.0-577.1, 581.8,
583.8, 590, 595.4–595.8, 597, 598.0, 601.2, 601.4, 603.1, 604,
614.2–614.4, 616.0-616.1, 616.3-616.5, 681–686, 711, 727.0,
727.3, 728.0, 730, 785.4, 790.7-790.8
Central Nervous System Infections 013, 036.0-036.1, 046–049, 053.0-053.1, 054.3, 054.7, 055.0,
056.0, 062–064, 072.1-072.2, 320–326, 331.5-331.6
Bacteremia Infections 036.2, 038, 790.7
Endocarditis and Pericarditis Infections 036.4, 420, 421
Hepatitis Infections 070, 573.1-573.2
Gastrointestinal Infections 007–009, 014, 054.2, 072.3, 120.1, 127, 129, 540.1, 567.0–567.2,
577.0-577.1
Genitourinary Infections
016, 054.1, 072.0, 078.6, 110.3, 112.1-112.2, 131, 581.8, 583.8,
590, 595.4–595.8, 597, 598.0, 601.2, 601.4, 603.1, 604,
614.2–614.4, 616.0-616.1, 616.3–616.5
Sexually Transmitted Infections 090–099, 447.7
Other Infections
001–006, 010–012, 015, 017-018, 020–027, 030–035, 037,
039–041, 045, 050–052, 053.2–053.9, 054.0, 054.4–054.9, 055,
056.7–056.9, 057, 060-061, 065-066, 071, 072.7–072.9, 073–077,
078.0–078.5, 078.7-078.8, 079–088, 100–104, 110.0–110.2,
110.4–110.9, 111, 112.0, 112.3–112.9, 114–118, 120.0,
120.2–120.9, 121–126, 128, 130, 132–136, 370.1, 370.3–370.5,
372.0-372.1, 373.4–373.6, 377.3, 380.1, 382, 383.0–383.2, 422,
460–466, 480-487, 511.1, 513, 681–686, 711, 727.0, 727.3, 728.0,
730, 785.4, 790.8
Neoplasms 140–239
Malignant Neoplasm of Breast 174-175
Malignant Neoplasm of CNS 191-192
Malignant Neoplasm of Thyroid Gland 193
Leukemia 204–208
Malignant Cancers of soft tissue, connective tissue and bone 170-171
Malignant Cancers of Skin 172-173
Endometrial Cancer 182
Other Malignant Neoplasms 140–169, 176–181, 183–190, 194–208
Benign Neoplasms 210–224, 225.0-225.1, 225.8-225.9, 226–229
Meningiomas 225.2–225.4
Carcinoma In Situ Tumours 230–234
Neoplasm of Uncertain Behavior 235–238
Neoplasm of Unspeciﬁed Nature 239
Endocrine Disorders 240–259
Thyroid Gland Disorders 240–246
Diabetes Mellitus 250
Hypothalamus/Pituitary Disorders 253
Adrenal Gland Disorders 255
Ovarian/Testicular Dysfunction Disorders 256-257
Other Endocrine Disorders 251-252, 254, 258-259
Nutritional Disorders 260–275, 278, 783
Malnutritional/Anorexic Disorders 260–263, 783.0, 783.2
Obesity Disorders 278.0-278.1, 783.1
Vitamin Deﬁciency Disorders 264–269Journal of Cancer Epidemiology 5
Table 2: Continued.
Infectious Disorders
001–136, 320–326, 370.1, 370.3–370.5, 372.0-372.1, 373.4–373.6,
377.3, 380.1, 382, 383.0–383.2, 420–422, 447.7, 460-466, 480-487,
511.1, 513, 540.1, 567.0-567.2, 573.1-573.2, 577.0-577.1, 581.8,
583.8, 590, 595.4–595.8, 597, 598.0, 601.2, 601.4, 603.1, 604,
614.2–614.4, 616.0-616.1, 616.3-616.5, 681–686, 711, 727.0,
727.3, 728.0, 730, 785.4, 790.7-790.8
Other Nutritional Disorders 270–275, 278.2–278.8, 783.3–783.9
Fluid And Electrolyte Disorders 276
Inherited Metabolic and Immune Disorders 277, 279
Hematologic Disorders 280, 281, 282–289, 325, 415.1, 444, 451–453, 790.0
Anaemias 280, 281, 282–285
Coagulation Defects 286-287, 325, 415.1, 444, 451–453
White Blood Cell Defects 288
Other Hematologic Disorders 289, 790.0
Psychiatric Disorders 293-298, 300-302, 306-309, 311-313, 314, 316
Depression Disorders 300.4, 309.0-309.1, 311, 313.1
Psychosis Disorders 293–298
Anxiety Disorders 300.0–300.3, 300.5–300.9, 308, 309.2, 313.0
Personality Disorders 301, 312
Eating Disorders 307.1–307.5
Hyperkinetic Syndrome (Attention Deﬁcit Hyperactivity
Disorders) 314
Other Psychiatric Disorders 302, 306, 307.0, 307.2–307.4, 307.6–307.9, 309.3–309.9,
313.2–313.9, 316
Substance Abuse 291-292, 303–305
Alcohol Abuse 291, 303
Drug Abuse 292, 304-305
Neurological Disorders 290, 299, 310, 315, 317–319, 327, 330, 331.0–331.5, 331.7–331.9,
332–337, 340-359, 430–437, 780-781, 784.0, 797
Cognitive Disorders 290, 299, 310, 315, 317–319, 797
Cerebral Degeneration Disorders 330, 331.0-331.2, 331.7–331.9
Hydrocephalus Disorders 331.3–331.5
Seizure Disorders 345, 780.3
Coma 780
Migraine and Headaches 346
Cerebrovascular Disorders 430–437
Spinal Cord Disorders 336, 344
Other Neurological Disorders 327, 784
Ent and Eye Disorders
360–369, 370.0, 370.2, 370.6–370.9, 371, 372.3–372.9,
373.0–373.3, 373.8-373.9, 374–376, 377.0–377.2, 377.4–377.9,
378-379, 380.0, 380.2–380.9, 381, 383.3–383.9, 384–389,
470–478, 526–529, 784.1–784.9
Eye and Adnexa Disorders
360–369, 370.0, 370.2, 370.6–370.9, 371, 372.3–372.9,
373.0–373.3, 373.8-373.9, 374–376, 377.0–377.2, 377.4–377.9,
378-379
Ear Disorders 380.0, 380.2–380.9, 381, 383.3–383.9, 384–387
Hearing Loss Disorders 388-389
Nasal and Oral Disorders 470–478, 526–529, 784.1–784.9
Cardiovascular Disorders 390–398, 401–414, 416-417, 423–429, 440–443, 446–448,
458-459, 785.0–785.3, 785.5, 785.9, 794.3
Cardiomyopathy and Heart Failure Disorders 425, 428
Arryhthmia Disorders 426-427, 785.0-785.1, 794.36 Journal of Cancer Epidemiology
Table 2: Continued.
Infectious Disorders
001–136, 320–326, 370.1, 370.3–370.5, 372.0-372.1, 373.4–373.6,
377.3, 380.1, 382, 383.0–383.2, 420–422, 447.7, 460-466, 480-487,
511.1, 513, 540.1, 567.0-567.2, 573.1-573.2, 577.0-577.1, 581.8,
583.8, 590, 595.4–595.8, 597, 598.0, 601.2, 601.4, 603.1, 604,
614.2–614.4, 616.0-616.1, 616.3-616.5, 681–686, 711, 727.0,
727.3, 728.0, 730, 785.4, 790.7-790.8
Hypertensive Disorders 401–405
Atherosclerotic Disorders 440
Ischaemic Heart Disorders 410–414
Hypotensive Disorders 458, 785.5
Other Cardiovascular Disorders 390–398, 416-417, 423-424, 429, 441–443, 446–448, 459,
785.2-785.3, 785.9
Varicose Veins, Haemorrhoids, and Lymphatic Disorders 454–457, 785.6
Varicose Veins and Hemorrhoids Disorders 454–456
Lymphatic Disorders 457, 785.6




530–537, 540.0, 540.9, 541–543, 550–553, 555–558, 560, 562,
564–566, 567.8–567.9, 568–572, 573.0, 573.3–573.9, 574–576,
577.2–577.9, 578-579, 787, 789
Irritable Bowel Disorders 555-556, 558
Liver Disorders 570–572, 573.0, 573.3–573.9
Biliary Tract and Gallbladder Disorders 574–576
Stomatitis 528
Esophagitis 530
Other Digestive System Disorders 530–537, 540.0, 540.9, 541–543, 550–553, 557, 560, 562, 564–566,
567.8-567.9, 568-569, 577.2–577.9, 578-579, 787, 789
Genitourinary Disorders
580, 581.0–581.3, 581.9, 582, 583.0–583.7, 583.9, 584–589,
591–594, 595.0–595.3, 595.9, 596, 598.1–598.9, 599-600,
601.0-601.1, 601.3, 601.8-601.9, 602, 603.0, 603.8-603.9, 605,
607-608, 788
Renal Disorders 580, 581.0–581.3, 581.9, 582, 583.0–583.7, 583.9, 584–589, 591
Calculus Disorders 592, 594
Bladder Disorders 595.0–595.3, 595.9, 596
Urethral Disorders 598.1–598.9, 599
Other Genitourinary Disorders 600, 601.0-601.1, 601.3, 601.8-601.9, 602, 603.0, 603.8-603.9,
605, 607-608, 788
Gynecological Disorders 614.0-614.1, 614.5–614.9, 615, 616.2, 616.8-616.9, 617–627, 629
Menstrual Disorders 626
Menopausal Disorders 627
Other Gynecological Disorders 614.0-614.1, 614.5–614.9, 615, 616.2, 616.8-616.9, 617–625, 629
Breast Disorders 611
Pregnancy, Childbirth, and Puerperium 630–648, 650–676, V22–V24, V27
Spontaneous Abortions 630–632, 634
Therapeutic Abortions 635–638
Ectopic Pregnancy 633
Complications Following Abortion, Ectopic, and Molar
Pregnancies 639Journal of Cancer Epidemiology 7
Table 2: Continued.
Infectious Disorders
001–136, 320–326, 370.1, 370.3–370.5, 372.0-372.1, 373.4–373.6,
377.3, 380.1, 382, 383.0–383.2, 420–422, 447.7, 460-466, 480-487,
511.1, 513, 540.1, 567.0-567.2, 573.1-573.2, 577.0-577.1, 581.8,
583.8, 590, 595.4–595.8, 597, 598.0, 601.2, 601.4, 603.1, 604,
614.2–614.4, 616.0-616.1, 616.3-616.5, 681–686, 711, 727.0,
727.3, 728.0, 730, 785.4, 790.7-790.8
Complications Related to Pregnancy 640–648
Indication for Care in Pregnancy, Labour and Delivery 650–659
Complications Occurring in Labour and Delivery 660–669
Complications of the Puerperium 670–676
Supervision and Pregnancy State V22–V24
Delivery Outcome V27
Infertility Disorders 606, 628, 792.2
Male Infertility 606, 792.2
Female Infertility 628
Perinatal Conditions 760–779, V30–V39
Perinatal Conditions 760–799
Birth Outcome V30–V39
Skin and Subcutaneous Disorders 680, 690–698, 700–709, 782
Hair and Hair Follicles Disorders 704
Other Skin and Subcutaneous Disorders 680, 690–698, 700–703, 705–709, 782
Musculoskeletal and Connective Tissue Disorders 710, 712–726, 727.1–727.2, 727.4–727.9, 728.1-728.2, 729,
731–739
Rheumatological Disorders 710, 712–716, 725-726
Joint Disorders 717–719
Spine Disorders 720–724, 737
Other Musculoskeletal and Connective Tissue Disorders 727.1-727.2, 727.4–727.9, 728.1–728.8, 729, 731–736, 738-739
Congenital Anomalies 740–759
Nonspeciﬁc Abnormal Findings 790.1–790.6, 790.9, 790.9, 791, 792.0-792.1, 792.3–792.9, 793,
794.0–794.2, 794.4–794.9, 795-796
Other and Unspeciﬁed Morbidity and Mortality 798-799
Injuries 800–848, 850–854, 860–887, 890–897, 900–904, 910–929,
940–959
Fractures (Excluding Skull and Spinal Fractures) 807–829
Head Injuries (Including Skull Fractures) 800–804, 850–854, 870–873, 900, 910, 918, 920-921, 925, 950-951
Spinal Injuries (Including Spinal Fractures) 805-806, 839–839.5, 846-847, 952–954
Burns 940–949
Other Injuries (Excluding Fractures) 830–838, 839.6–839.9, 840–845, 848, 860–869, 874–887,
890–897, 901–904, 911–917, 919, 922–924, 926–929, 955–959
Poisonings by Drugs, Medicaments, and Biological Substances 960–979
Eﬀects of Foreign Body Entering Through Oriﬁce 930–939
Toxic Eﬀects of Substances 980–989
Other and Unspeciﬁed Eﬀects of External Causes 990–994
Certain Adverse Eﬀects Not Elsewhere Classiﬁed 995
Adverse Eﬀects Due to Drug, Medicament, or Biological
Substance 995.0, 995.2, 995.4
Other Adverse Eﬀects 995.1, 995.3, 995.5, 995.88 Journal of Cancer Epidemiology
Table 2: Continued.
Infectious Disorders
001–136, 320–326, 370.1, 370.3–370.5, 372.0-372.1, 373.4–373.6,
377.3, 380.1, 382, 383.0–383.2, 420–422, 447.7, 460-466, 480-487,
511.1, 513, 540.1, 567.0-567.2, 573.1-573.2, 577.0-577.1, 581.8,
583.8, 590, 595.4–595.8, 597, 598.0, 601.2, 601.4, 603.1, 604,
614.2–614.4, 616.0-616.1, 616.3-616.5, 681–686, 711, 727.0,
727.3, 728.0, 730, 785.4, 790.7-790.8
Complications from a Procedure or Device 996–998
Complications of Medical Care 999
Late Eﬀects 137–139, 268.1, 326, 438, 905-909, E929, E959, E969, E977, E989,
E999
Late Eﬀects of Infectious and Parasitic Diseases 137–139
Late Eﬀects of Ricketts 268.1
Late Eﬀects of Intracranial Abscess or Pyogenic Infection 326
Late Eﬀects of Cerebrovascular Disease 438
Late Eﬀect of Poisoning Due to Drug, Medicament, or Biological
Substance 909.0
Late Eﬀect of Toxic Eﬀects of Nonmedical Substances 909.1
Late Eﬀects of Radiation 909.2
Late Eﬀects of Complications of Surgical and Medical Care 909.3
Late Eﬀects of Other and Unspeciﬁed Causes 909.4–909.9
Late Eﬀects of Injuries 905–908
Late Eﬀects of Accidental Injury E929
Late Eﬀects of Self-Inﬂicted Injury E959
Late Eﬀects of Injury Purposely Inﬂicted by Other Person E969
Late Eﬀects of Injuries Due to Legal Intervention E977
Late Eﬀects of Injury, Undetermined Whether Accidentally or
Purposely Inﬂicted E989
Late Eﬀects of Injury Due to War Operations E999
External Causes (E Code) (Supplementary Codes)
External Causes of Injury E800–E807, E810–E838, E840–E848, E880–E888, E890–E928,
E970–E976, E978, E980–E988, E990–E998
Railway Accidents E800–E807
Motor Vehicle Accidents-Traﬃc and Nontraﬃc E810–E825
Pedal Cycle Accidents E826
Other Transport Accidents E827–E838, E840–E848
All Accidental Falls E880–E888
All Accidents Caused by Fire and Flames E890–E899
All Other Accidents E900–E928
All Injuries Caused by Legal Intervention E970–E976, E978
Injury Undetermined Whether Accidentally or Purposely
Inﬂicted E980–E988
Injury Resulting From Operations of War E990–E998
External Causes Of Poisoning By Drugs, Medicaments, And
Biologicals E850–E858
External Causes Of Poisoning By Solid And Liquids, Gases And
Vapours E860–E869
Accidental Poisoning by Alcohol, Not Elsewhere Classiﬁed E860
Other Accidental Poisonings E861–E869Journal of Cancer Epidemiology 9
Table 2: Continued.
Infectious Disorders
001–136, 320–326, 370.1, 370.3–370.5, 372.0-372.1, 373.4–373.6,
377.3, 380.1, 382, 383.0–383.2, 420–422, 447.7, 460-466, 480-487,
511.1, 513, 540.1, 567.0-567.2, 573.1-573.2, 577.0-577.1, 581.8,
583.8, 590, 595.4–595.8, 597, 598.0, 601.2, 601.4, 603.1, 604,
614.2–614.4, 616.0-616.1, 616.3-616.5, 681–686, 711, 727.0,
727.3, 728.0, 730, 785.4, 790.7-790.8
Misadventures To Patients During Surgical And Medical Care E870–E876
Abnormal Reaction Or Complication To Patient After Surgical Or
Medical Care E878-E879
Adverse Eﬀects In Therapeutic Use Of Drugs, Medicaments, And
Biologicals E930–E949
Chemotherapy Adverse Eﬀects E930.7–E933.1
Other Adverse Eﬀects E930.0–E930.6, E930.8-E930.9, E931-E932, E933.0,
E933.2–E933.9, E934–E949
Suicides And Self-Inﬂicted Injury E950–E958
Homicide And Injury Purposely Inﬂicted By Other Persons E960–E968
Factors Inﬂuencing Health Status And Contact With Health
Services (V Code) V01–V21, V25-V26, V28, V40–V82
Personal History of Malignant Neoplasm V10
Family History of Malignant Neoplasm V16
Personal History of Mental Disorder V11
Mental and Behavioral Problems V40
Health Supervision of Infant or Child V20
Constitutional States In Development V21
Problems With Sight V41.0-V41.1
Problems With Hearing V41.2-V41.3
Elective Surgery for Purposes Other Than Remedying Health
States V50, V51
Fitting and Adjustment of Hearing Aid V53.2
Fitting and Adjustment of Cardiac Pacemaker V53.3
Radiotherapy Session V58.0
Maintenance Chemotherapy V58.1
Housing, Household, and Economic Circumstances V60.0-V60.2
Other Family Circumstances V61
Unemployment V62.0
Observation For Suspected Malignant Neoplasm V71.1
Special Screening For Malignant Neoplasms V76
Other Factors Inﬂuencing Health Status and Contact With
Health Services
V01–V09, V12–V15, V17–V19, V25-V26, V28, V41.4–V41.9,
V42–V49, V52, V53.0-V53.1, V53.4–V53.9, V54–V57,
V58.2–V58.9, V59, V60.3–V60.9, V62.1–V62.9, V63–V70, V71.0,
V71.2–V71.9, V72–V75, V77–V82
Morphology Of Neoplasms (M Codes) M8000-M9970
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